Protein kinase C inhibitors.

被引：103

作者：

Swannie H.C. ^{[1
]}

Kaye S.B. ^{[1
]}

机构：

[1] CRC Department of Medical Oncology, Royal Marsden Hospital, Surrey, SM2 5NG, Sutton

来源：

Current Oncology Reports | 2002年 / 4卷 / 1期

关键词：

Paclitaxel; Maximum Tolerate Dose; Miltefosine; Proc ASCO; Safingol;

D O I：

10.1007/s11912-002-0046-7

中图分类号：

学科分类号：

摘要：

Protein kinase C (PKC) is a family of serine-threonine protein kinases that are involved in signal transduction pathways that regulate growth factor response, proliferation, and apoptosis. Its central role in these processes, which are closely involved in tumor initiation, progression, and response to antitumor agents, makes it an attractive therapeutic target in cancer. Despite initial activity seen in melanoma (bryostatin and UCN-01), non-Hodgkin's lymphoma (ISIS 3521, bryostatin, and UCN-01), and ovarian carcinoma (ISIS 3521 and bryostatin) in phase I studies, single-agent activity in those phase II studies reported to date has been limited. Preclinical data highlight a role for PKC in modulation of drug resistance and synergy with conventional cytotoxic drugs. A randomized phase III study of ISIS 3521 in combination with carboplatin and paclitaxel, compared with chemotherapy alone, in advanced non-small-cell lung cancer is underway. This paper reviews the rationale for using PKC inhibitors in cancer therapy, the challenges for clinical trial design, and the recent clinical experience with modulators of PKC activity.

引用

页码：37 / 46

页数：9

共 234 条

[1]

Cartee L(2000)Protein kinase C modulation and anticancer drug response Cancer Invest 18 731-739

[2]

Kucera GL(1999)Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors, and agents in development Curr Med Chem 6 877-903

[3]

Goekjian PG(1982)Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters J Biol Chem 257 7847-7851

[4]

Jirousek MR(1984)The role of protein kinase C in cell surface signal transduction and tumour promotion Nature 308 693-698

[5]

Castagna M(1994)Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C Cancer Res 54 1707-1714

[6]

Takai Y(2001)Modulation of protein kinase C in antitumor treatment Rev Physiol Biochem Pharmacol 142 1-96

[7]

Kaibachi K(1999)Ribozyme inhibition of the protein kinase C alpha triggers apoptosis in glioma cells Br J Cancer 80 1558-1564

[8]

Nishizuka Y(1998)Telomerase is controlled by protein kinase Calpha in human breast cancer cells J Biol Chem 273 33436-33442

[9]

Jarvis WD(1997)Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture Biochem Biophys Res Commun 241 730-736

[10]

Turner AJ(1989)Biology of the protein kinase C family Cancer Metastasis Rev 8 199-214

← 1 2 3 4 5 6 7 8 9 10 →